GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France

GenSight Biologics Announces the Filing of its 2024 Universal Registration Document

GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update

GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation

GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France

GenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ®

GenSight Biologics Granted Six-Month Extension in LUMEVOQ® European Regulatory Review

GenSight Biologics Provides Update on LUMEVOQ® Manufacturing Timeline

GenSight Biologics Announces Extension of Day 120 Clock Stop of LUMEVOQ® EMA Regulatory Filing; MAA Review to Resume in April 2022

GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa